Established in Hyderabad, India in 1978, Gland Pharma has grown over the years from a contract manufacturer of small volume liquid parenteral products, to become one of the largest and fastest growing injectable-focused companies, with a global footprint across 60 countries, including the United States, Europe, Canada, Australia, India and other markets. We operate primarily under a business to business (B2B) model and have an excellent track record in the development, manufacturing and marketing of complex injectables. This presence across the value chain has helped us witness exponential growth. We are promoted by Shanghai Fosun Pharma, a global pharmaceutical major.
With our proven performance in complex injectables across development, manufacturing and marketing, we are sufficiently enabled to meet diverse injectable needs across a vast range of specific requirements. Our 22 production lines for finished formulations across four facilities are complimented by three facilities for Active Pharmaceutical Ingredients (API). Plans are underway to augment the present manufacturing capacity of approximately 750 million units in the medium term to support future growth.
The ability to provide therapeutic medicines on the best quality parameters and at the right price, is the overriding objective for us at Gland Pharma. All other factors remaining equal, backward integration and economies of scale play a significant role in providing quality medications at the right price. Over the years, we have been able to move ahead on both those counts, to establish a presence across the entire value chain in Injectables.
A manufacturing base with installed capacity of 750 million units per annum spread over seven facilities; proven Research and Development wing; pan-India and global distribution and sales network; affiliation with national and state level healthcare institutions; compliance with all necessary regulatory boards; and a high level of approvals and pending filings in our area of operations, all contribute to our standing in the pharma domain.
Our family of investors and other stakeholders are the driving force that gives us a sharp focus on good governance in all our areas of operations and services. And by doing so, we are reiterating our firm resolve to deliver value and satisfaction.
PVN Raju is a Graduate in Chemistry from the Presidency College of Madras and a Post Graduate from the Indian Institute of Chemists. He received training at Evans Medical in the UK and Pharmacia in Sweden, before starting Gland Chemicals in 1974 and Gland Pharma in 1978.
The visionary technocrat pioneered Heparin technology in India in 1960, and set up the country’s first state-of-the-art Pre-Filled Syringe (PFS) facility for LMWHs in 1998. It was under his guidance that the facility received USFDA acceptance in 2003, another first in India.
His associations include Life Membership of the Indian Pharmaceutical Association (IPA); Parenteral Drug Association (PDA), USA; and International Society for Pharmaceutical Engineering (ISPE).
His honorary recognitions include:
After obtaining his MBBS degree from Osmania University (India), Dr Ravi specialized in Science of Medicine from East Carolina University School of Medicine (USA). After seven years’ hospital-based practice there, he joined Gland Pharma as its Executive Director in 1992.
Assuming the mantle of the company’s Managing Director in 1999, Dr Ravi spearheaded its rapid, multi-dimensional growth over the next two decades.
Displaying great foresight and vision, he was instrumental in setting up a comprehensive infrastructure for Research & Development (Analytical and Formulations), as well as Contract Manufacture of a wide range of injectable dosage forms in compliance with the stringent regulatory requirements of the company’s business partners from across the world.
In recognition of his deep and extensive knowledge and experience in the pharmaceutical sector, Dr Ravi has been honoured with several institutional memberships and awards.